Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Format:	Journal article
Veröffentlicht:	Oxford University Press 2017

Ähnliche Einträge

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
von: Travis, S, et al.
Veröffentlicht: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
von: Travis, S, et al.
Veröffentlicht: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
von: Travis, S, et al.
Veröffentlicht: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
von: Sandborn, W, et al.
Veröffentlicht: (2016)

Does it all ADA up? Adalimumab for ulcerative colitis.
von: Travis, S
Veröffentlicht: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
von: Walsh, A, et al.
Veröffentlicht: (2018)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
von: Napolitano M, et al.
Veröffentlicht: (2022-06-01)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
von: Renata de Medeiros Dutra, et al.
Veröffentlicht: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
von: David T. Rubin, et al.
Veröffentlicht: (2021-05-01)

Raising the bar in ulcerative colitis management
von: Fabrizio Fanizzi, et al.
Veröffentlicht: (2024-11-01)

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
von: Dongyeol Shin, et al.
Veröffentlicht: (2018-09-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
von: Ferdinando D’Amico, et al.
Veröffentlicht: (2019-05-01)

A Case of Syrian Child with Cerebral Infarction as an Extraintestinal Manifestation of Ulcerative Colitis
von: Riham Salloum, et al.
Veröffentlicht: (2019-01-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
von: Yiyoung Kwon, et al.
Veröffentlicht: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
von: K. Hata, et al.
Veröffentlicht: (2019-08-01)

Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis
von: Francesca Bernardi, et al.
Veröffentlicht: (2024-12-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
von: Eun Young Park, et al.
Veröffentlicht: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
von: Jesús K. Yamamoto-Furusho, et al.
Veröffentlicht: (2020-10-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
von: Eun Soo Kim
Veröffentlicht: (2021-03-01)

Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
von: Ma’In Atallah Mohammad Abumuhfouz, et al.
Veröffentlicht: (2024-04-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
von: Natsuki Ishida, et al.
Veröffentlicht: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
von: Laurel L. Wessman, BS, et al.
Veröffentlicht: (2017-07-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
von: Assasi Nazila, et al.
Veröffentlicht: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
von: Armuzzi A, et al.
Veröffentlicht: (2013-04-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
von: Freeman HJ
Veröffentlicht: (2013-11-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
von: Zhdanava M, et al.
Veröffentlicht: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
von: Vuitton, L, et al.
Veröffentlicht: (2017)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Veröffentlicht: (2016-03-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
von: Sebastian Hoffmann, et al.
Veröffentlicht: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
von: Patrícia ZACHARIAS, et al.
Veröffentlicht: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
von: Jacky Ng, et al.
Veröffentlicht: (2021-01-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
von: Chengdong Yu, et al.
Veröffentlicht: (2024-02-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
von: Shinji Okabayashi, et al.
Veröffentlicht: (2017-10-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
von: Muhammed B. Durak, et al.
Veröffentlicht: (2025-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
von: Bénédicte Caron, et al.
Veröffentlicht: (2023-01-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
von: Travis, S, et al.
Veröffentlicht: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
von: Joseph J. LaConti, et al.
Veröffentlicht: (2016-01-01)

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
von: Saleh Azadbakht, et al.
Veröffentlicht: (2024-07-01)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
von: Candace L. Beilman, et al.
Veröffentlicht: (2016-01-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
von: Martin Wasserbauer, et al.
Veröffentlicht: (2022-01-01)